Patients 'put at risk by lack of cancer trials data'
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Cancer patients are being put at risk because of the refusal of drug companies to publish the results of clinical trials, scientists claimed yesterday.
Cancer patients are being put at risk because of the refusal of drug companies to publish the results of clinical trials, scientists claimed yesterday.
Research suggests data from more than a quarter of cancer trials never reaches the public domain because drug companies suppress negative findings or try to prevent rival companies learning too much about their products.
Richard Sullivan, head of clinical programmes at Cancer Research UK, said: "The medical community needs to know the results of clinical trials to be able to view the entire picture of how a treatment works, how it compares to other therapies and what choices could serve patients best. It's disturbing to think that important information on clinical trials is being left to gather dust."
A study of 500 cancer trials found that 26 per cent had failed to publish their full results five years after presenting early date at a leading American conference according to Dr Sullivan. "That is data from 47,000 patients who gave their consent to be involved in the research that was wasted. It is shocking," Dr Sullivan told the British Association Festival of Science meeting in Exeter.
Trial investigators cited lack of time and shortage of funds as their main reasons for not publishing. But Dr Sullivan said there was a perception among drug companies that publishing early data might help the competition. He called for a database of all clinical trials to be established so the information was in the public domain.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments